Video

Dr. Abedin on the Role of Venetoclax Plus Obinutuzumab in CLL

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the role of venetoclax plus obinutuzumab in chronic lymphocytic leukemia.

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the role of venetoclax (Venclexta) plus obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL).

In May 2019, the FDA approved the combination of venetoclax and obinutuzumab for the frontline treatment of patients with CLL or small lymphocytic lymphoma. This is great for patients, Abedin says, mainly because frontline ibrutinib (Imbruvica)-based regimens can be toxic. The BTK inhibitor can cause bleeding, nausea, and atrial fibrillation, so having an alternative in the frontline setting is important.

However, there are more data supporting the use of ibrutinib in this setting, Abedin notes. Two randomized trials have compared ibrutinib with the previous standard of care, and there are more follow-up data with the drug as opposed to the newly approved venetoclax/obinutuzumab combination. The current data with the novel combination show promising response rates and depth of response, Abedin concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity